

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Zhejiang Neo-Dankong Pharmaceutical Co. Ltd	10/25/2006
RECEIVING PARTY DATA	
Name:	Arrow International Limited
Street Address:	57 St. Christopher Street
City:	Valetta
State/Country:	MALTA
Postal Code:	VLT 08
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	11504103
CORRESPONDENCE DATA	
Fax Number:	(202)371-2540
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	202-371-2600
Email:	resmond@skgf.com
Correspondent Name:	Sterne, Kessler, Goldstein & Fox PLLC
Address Line 1:	1100 New York Avenue, NW
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005
ATTORNEY DOCKET NUMBER:	2372.0070000
NAME OF SUBMITTER:	/Robert W Esmond/
Total Attachments: 2 source=2372.0070000 Assignment for Company#page1.tif source=2372.0070000 Assignment for Company#page2.tif	

OP \$40.00 11504103

500529402

PATENT
REEL: 020890 FRAME: 0974

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, **Zhejiang Neo-Dankong Pharmaceutical Co. Ltd.**, a corporation organized and existing under the laws of China and having an office and place of business at 83 Jiefang North Road, Jiaojiang District of Taizhou, Zhejiang Prov 31800, China (hereafter referred to as the "Assignor"), hereby sells and assigns to **Arrow International Limited**, a corporation formed under the laws of Malta, having an office and place of business at 57 St. Christopher Street, Valetta, Malta VLT 08 (hereafter referred to as the "Assignee"), an undivided, one-half of the right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world,

(a) in the invention(s) known as **Crystalline Sodium Atorvastatin** for which application(s) for patent in the United States of America has a filing date of August 15, 2006 (also known as United States Application No. 11/504,103), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns together with the Assignor.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the applications or

Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement act.

The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee jointly with the Assignor.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment, any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

SIGNED on behalf of the said ASSIGNOR,

ZHEJIANG NEO-DANKONG
PHARMACEUTICAL CO. LTD.

By: Huabin Hong
Name: Huabin Hong
Title: Director
Date: Oct. 25, 2006

585962_1.DOC